Amicus upgraded to Buy at Needham banking on kidney disease therapy

Amicus Therapeutics (NASDAQ:FOLD) was upgraded to Buy from Hold at Needham with a $14 target, emphasizing that the company's kidney disease program, DMX-200, is undervalued. The stock of the company is up about 5% today. "Despite DMX-200 being a Phase ...